Literature DB >> 6692412

Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system.

F R Balkwill, E M Moodie.   

Abstract

Human lymphoblastoid interferon strongly increased the anti-tumor activity of suboptimal doses of two commonly used anti-cancer drugs, cyclophosphamide and Adriamycin, on a human breast tumor xenograft growing in nude mice. A combination of human lymphoblastoid interferon with either of these agents caused regression and in some cases total disappearance of tumors at doses of drug and interferon that, used singly, were capable only of inhibiting tumor growth. The combined therapy also resulted in a greatly increased survival. Studies with interferon and cyclophosphamide indicated that the antitumor activity was greatest when the two agents were administered simultaneously rather than sequentially.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692412

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

Authors:  M J Lind; S Gomm; A P Simmonds; L Ashcroft; A Kamthan; H Gurney; N Thatcher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Interferons: current status and future directions of this prototypic biological.

Authors:  R V Smalley; E C Borden
Journal:  Springer Semin Immunopathol       Date:  1986

3.  Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.

Authors:  R L Marquet; J Jeekel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

Review 4.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Alpha interferon: a look to the future.

Authors:  E M Bonnem
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

Authors:  M R Cooper; A Fefer; J Thompson; D C Case; R Kempf; R Sacher; J Neefe; J Bickers; J H Scarffe; R J Spiegel
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 7.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

8.  Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy.

Authors:  X Cao; J Wang; W Zhang; G Chen; X Kong; K Tani
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

10.  Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.

Authors:  P Puddu; C Locardi; P Sestili; F Varano; C Petrini; A Modesti; L Masuelli; I Gresser; F Belardelli
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.